Professor Chris Twelves is Professor of Clinical Cancer Pharmacology and Oncology and Head of Section of Oncology and Clinical Research at the Leeds Cancer Research UK Centre.
He is a medical oncologist with a particular interest in new drug development and clinical pharmacology; his clinical practice has been in colorectal and breast cancer.
After training as an oncologist in London he was Senior Lecturer, then Reader, in Medical Oncology in Glasgow at the Beatson Oncology Centre before taking up his current post at the University of Leeds and St James’s Institute of Oncology.
Prof Twelves heads the Experimental Cancer Medicine Centre in Leeds and has been a member of the Cancer Research UK New Agents Committee and Chair of the New Drug Development Group of the EORTC.
He has been involved in the development of several important new agents including capecitabine, and eribulin. Professor Twelves has a particular interest in early clinical trials and pharmacokinetics including intra-tumoural drug pharmacokinetics.
Professor Twelves has published over 200 papers in journals including the New England Journal of Medicine, Lancet and Journal of Clinical Oncology and spoken at numerous international meetings.
He has also edited, or contributed to, several books including one on Phase I clinical trials and another on the design of Phase II clinical trials.